John K. Clarke's most recent trade in Atyr Pharma Inc was a trade of 24,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 22, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atyr Pharma Inc | John K. Clarke | Director | 22 May 2024 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | ||
| Atyr Pharma Inc | John K. Clarke | Director | 17 May 2023 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | ||
| Atyr Pharma Inc | John K. Clarke | Director | 26 Apr 2023 | 6,000 | 0 | - | - | Restricted Stock Unit | ||
| Atyr Pharma Inc | John K. Clarke | Director | 26 Apr 2023 | 6,000 | 19,797 (0%) | 0% | - | Common Stock | ||
| Atyr Pharma Inc | John K. Clarke | Director | 26 Apr 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units | ||
| Atyr Pharma Inc | John K. Clarke | Director | 21 May 2021 | 2,500 | 108,083 (1%) | 0% | 4.3 | 10,850 | Common Stock | |
| Atyr Pharma Inc | John K. Clarke | Director | 28 Apr 2021 | 1,428 | 1,428 | - | - | Stock Option (right to buy) |